Polydeoxyribonucleotide (PDRN): A safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2009, Pages 313-321

  Altavilla, Domenica ^a   Bitto, Alessandra ^a   Polito, Francesca ^a   Marini, Herbert ^a   Minutoli, Letteria ^a   Di Stefano, Vincenzo ^c   Irrera, Natasha ^c   Cattarini, Giulia ^b   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Mastelli Srl   (Italy)

^c NONE

Author keywords

Diabetic foot ulcer; Peripheral artery occlusive disease (PAOD); Polideoxyribonucleotide (PDRN); Therapeutic angiogenesis

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ANGIOGENIC FACTOR; POLYDEOXYRIBONUCLEOTIDE; VASCULOTROPIN;

ANGIOGENESIS; BURN; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC FOOT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GENE THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LEG AMPUTATION; LIMB ISCHEMIA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE PERFUSION; TREATMENT FAILURE; WOUND HEALING; WOUND HEALING IMPAIRMENT; DRUG EFFECT; PERIPHERAL VASCULAR DISEASE;

ANGIOGENESIS INDUCING AGENTS; ARTERIAL OCCLUSIVE DISEASES; DIABETIC FOOT; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; POLYDEOXYRIBONUCLEOTIDES; WOUND HEALING;

EID: 74049097935     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789541909     Document Type: Review

References (55)

1. Insull, W., Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am. J. Med., 2009, 122(1 Suppl.), S3.
2. Criqui, M.H.; Alberts, M.J.; Fowkes, F.G.; Hirsch, A.T.; O'Gara, P.T.; Olin, J.W.; American Heart Association Writing Group 2. Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? Circulation, 2008, 118, 2830.
3. Lovell, M.; Harris, K.; Forbes, T; Twillman, G.; Abramson, B.; Criqui, M.H.; Schroeder, P.; Mohler Iii, E.R.; Hirsch, A.T.; on behalf of the Peripheral Arterial Disease Coalition. Peripheral arterial disease: lack of awareness in Canada. Can. J. Cardiol., 2009, 25, 39.
4. Allison, M.A.; Ho, E.; Denenberg, J.O.; Langer, R.D.; Newman, A.B.; Fabsitz, R.R.; Criqui, M.H. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am. J. Prev. Med., 2007, 32, 328.
5. Creager, M.A.; White, C.J.; Hiatt, W.R.; Criqui, M.H.; Josephs, S.C.; Alberts, M.J.; Pearce, W.H.; Gray, B.H.; Rocha-Singh, K.J.; American Heart Association. Atherosclerotic peripheral vascular disease symposium II: executive summary. Circulation, 2008, 118, 2811.
6. Criqui, M.H.; Ninomiya, J.K.; Wingard, D.L.; Ji, M.; Fronek, A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J. Am. Coll. Cardiol. 2008, 52, 1736.
7. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27, 1047.
8. Singh, N.; Armstrong, D.G.; Lipsky, B.A. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. JAMA, 2005, 293, 217.
9. Jones, K.R.; Fennie, K.; Lenihan, A. Evidence-based management of chronic wounds. Adv. Skin Wound Care, 2007, 20, 591.
10. Reiber, G.E.; Raugi, G.J. Preventing foot ulcers and amputations in diabetes. Lancet, 2005, 366, 1676.
11. Franz, M.G.; Robson, M.C.; Steed, D.L.; Barbul, A.; Brem, H.; Cooper, D.M.; Leaper, D.; Milner, S.M.; Payne, W.G.; Wachtel, T.L.; Wiersema-Bryant, L.; Wound Healing Society. Guidelines to aid healing of acute wounds by decreasing impediments of healing. Wound Repair. Regen., 2008, 16, 723.
12. Losordo, D.W.; Dimmeler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation, 2004, 109, 2487.
13. Losordo, D.W.; Dimmeler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation, 2004, 109, 2692.
14. Testa, U.; Pannitteri, G.; Condorelli, G.L. Vascular endothelial growth factors in cardiovascular medicine. J. Cardiovasc. Med. (Hagerstown)., 2008, 9, 1190.
15. Bao, P.; Kodra, A.; Tomic-Canic, M.; Golinko, M.S.; Ehrlich, H.P.; Brem, H. The role of vascular endothelial growth factor in wound healing. J. Surg. Res., 2008, 153, 347.
16. Khakh, B.S.; Burnstock, G.; Kennedy, C.; King, B.F.: North, R.A.; Séguéla, P.; Voigt, M.; Humphrey, P.P. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev., 2001, 53, 107.
17. Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53, 527.
18. Schulte, G.; Fredholm, B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal., 2003, 15, 813.
19. Burnstock, G. Purinergic signalling. Br. J. Pharmacol., 2006, 147(Suppl. 1), S172.
20. Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov., 2006, 5, 247.
21. Pagès, G.; Pouysségur, J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene - a concert of activating factors. Cardiovasc. Res., 2005, 65, 564.
22. Déry, M.A.; Michaud, M.D.; Richard, D.E. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol., 2005, 37, 535.
23. De Ponti, C.; Carini, R.; Alchera, E.; Nitti, M.P.; Locati, M.; Albano, E.; Cairo, G.; Tacchini, L. Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. J. Leukoc. Biol., 2007, 82, 392.
24. Ramanathan, M.; Pinhal-Enfield, G.; Hao, I.; Leibovich, S.J. Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol. Biol. Cell, 2007, 18, 14.
25. Ham, J.; Rees, D.A. The adenosine a2b receptor: its role in inflammation. Endocr. Metab. Immune Disord. Drug Targets, 2008, 8, 244.
26. Linden, J. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol., 2005, 67, 1385.
27. Desai, A.; Victor-Vega, C.; Gadangi, S.; Montesinos, M.C.; Chu, C.C.; Cronstein, B.N. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol. Pharmacol., 2005, 67, 1406.
28. Feoktistov, I.; Ryzhov, S.; Zhong, H.; Goldstein, A.E.; Matafonov, A.; Zeng, D.; Biaggioni, I. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension, 2004, 44, 649.
29. Tonello, G.; Daglio, M.; Zaccarelli, N.; Sottofattori, E.; Mazzei, M.; Balbi, A. Characterization and quantitation of the active polynucleotide fraction (PDRN) from human placenta, a tissue repair stimulating agent. J. Pharm. Biomed. Anal., 1996, 14, 1555.
30. Bianchini, P.; Tellini, N.; Morani, A.M.; Folloni, M.G. Pharmacological data on polydeoxyribonucleotide of human placenta. Int. J. Tissue React., 1981, 3, 151.
31. Tammela, T.; Enholm, B.; Alitalo, K.; Paavonen, K. The biology of vascular endothelial growth factors. Cardiovasc. Res., 2005, 65, 550.
32. Jo ko, J.; Mazurek, M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med. Sci. Monit., 2004, 10, RA89.
33. Rasmussen, H.S.; Rasmussen, C.S.; Macko, J.; Yonehiro, G. Angiogenic gene therapy strategies for the treatment of cardiovascular disease. Curr. Opin. Mol. Ther., 2002, 4, 476.
34. Kalka, C.; Baumgartner, I. Gene and stem cell therapy in peripheral arterial occlusive disease. Vasc. Med., 2008, 13, 157.
35. Seale, T.W.; Abla, K.A.; Shamim, M.T.; Carney, J.M.; Daly, J.W. 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. Life Sci., 1988, 43, 1671.
36. Waters, R.E.; Terjung, R.L.; Peters, K.G.; Annex, B.H. Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents. J. Appl. Physiol., 2004, 97, 773.
37. Taniyama, Y.; Morishita, R.; Hiraoka, K.; Aoki, M.; Nakagami, H.; Yamasaki, K.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation, 2001, 104, 2344.
38. Bitto, A.; Polito, F.; Altavilla, D.; Minutoli, L.; Migliorato, A.; Squadrito, F. Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease. J. Vasc. Surg., 2008, 48, 1292.
39. Liu, Z.J.; Velazquez, O.C. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid. Redox Signal, 2008, 10, 1869.
40. Barrientos, S.; Stojadinovic, O.; Golinko, M.S.; Brem, H.; Tomic-Canic, M. Growth factors and cytokines in wound healing. Wound Repair Regen., 2008, 16, 585.
41. Altavilla, D.; Saitta, A.; Cucinotta, D.; Galeano, M.; Deodato, B.; Colonna, M.; Torre, V.; Russo, G.; Sardella, A.; Urna, G.; Campo, G.M.; Cavallari, V.; Squadrito, G.; Squadrito, F. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes, 2001, 50, 667.
42. Guizzardi, S.; Galli, C.; Govoni, P.; Boratto, R.; Cattarini, G.; Martini, D.; Belletti, S.; Scandroglio, R. Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair. Life Sci., 2003, 73, 1973.
43. Raposio, E.; Guida, C.; Coradeghini, R.; Scanarotti, C.; Parodi, A.; Balzelli, I.; Fiocca, R.; Santi, P.L. Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair. Cell Prolif., 2008, 41, 739.
44. Muratore, O.; Cattarini, G.; Gianoglio, S.; Tonoli, E.L.; Saccà, S.C.; Ghiglione, D.; Venzano, D.; Ciurlo, C.; Lantieri, P.B.; Schito, G.C. A human placental polydeoxyribonucleotide (PDRN) may promote the growth of human corneal fibroblasts and iris pigment epithelial cells in primary culture. New Microbiol., 2003, 26, 13.
45. Thellung, S.; Florio, T.; Maragliano, A.; Cattarini, G.; Schettini, G. Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes. Life Sci., 1999, 64, 1661.
46. Valls, M.D.; Cronstein, B.N.; Montesinos, M.C. Adenosine receptor agonists for promotion of dermal wound healing. Biochem. Pharmacol., 2008, 77, 1117.
47. Macero, L.; Pinhal-Enfield, G.; Alshits, V.; Elson, G.; Cronstein, B.N.; Leibovich, S.J. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am. J. Pathol., 2007, 171, 1774.
48. Montesinos, M.C.; Shaw, J.P.; Yee, H.; Shamamian, P.; Cronstein, B.N. Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am. J. Pathol., 2004, 164, 1887.
49. Montesinos, M.C.; Desai, A.; Chen, J.F.; Yee, H.; Schwarzschild, M.A.; Fink, J.S.; Cronstein, B.N. Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am. J. Pathol., 2002, 160, 2009.
50. Galeano, M.; Bitto, A.; Altavilla, D.; Minatoli, L.; Polito, F.; Calò, M.; Lo Cascio, P.; Stagno d'Alcontres, F.; Squadrito, F. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair Regen., 2008, 16, 208.
51. Bitto, A.; Galeano, M.; Squadrito, F.; Minutoli, L.; Polito, F.; Dye, J.F.; Clayton, E.A.; Calò, M.; Venuti, F.S.; Vaccaro, M.; Altav illa, D. Polydeoxyribonucleotide improves angiogenesis and wound healing in experimental thermal injury. Crit. Care Med., 2008, 36, 1594.
52. Lazzarotto, M.; Tomasello, E.M.; Caporossi, A. Clinical evaluation of corneal epithelialization after photorefractive keratectomy in patients treated with polydeoxyribonucleotide (PDRN) eye drops: a randomized, double-blind, placebo-controlled trial. Eur. J. Ophthalmol., 2004, 14, 264.
53. Rubegni, P.; De Aloe, G.; Mazzatenta, C.; Cattarini, L.; Fimiani, M. Clinical evaluation of the trophic effect of polydeoxyribonucleotide (PDRN) in patients undergoing skin explants. A Pilot Study. Curr. Med. Res. Opin., 2001, 17, 128.
54. Valdatta, L.; Thione, A.; Montarino, C.; Buoro, M.; Tuinder, S. Evaluation of the efficacy of polydeoxyribonucleotides in the healing process of autologous skin graft donor sites: a pilot study. Curr. Med. Res. Opin., 2004, 20, 403.
55. De Aloe, G.; Rubegni, P.; Biagioli, M.; Taddeucci, P.; Fimiani, M.; Skin graft donor site and use of polydeoxyribonucleotide as a treatment for skin regeneration: a randomized, controlled, doubleblind, clinical trial. Wounds, 2004, 16, 1.